Ovarian Cancer Stage III
13
6
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
7.7%
1 terminated out of 13 trials
66.7%
-19.8% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (13)
Prehabilitation in Gynaecological Cancer Patients
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Tumor Microenvironment in Ovarian Cancer
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
Self-Advocacy Serious Game in Advanced Cancer
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer